PMID- 34581158
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2980-3187 (Electronic)
IS  - 0494-1373 (Linking)
VI  - 69
IP  - 3
DP  - 2021 Sep
TI  - [The role of fixed dose combinations of inhaled cortikosteroids, long acting 
      beta-2 agonists, and long acting muscarinic antagonists (ICS/LABA/LAMA) in the 
      treatment of asthma].
PG  - 369-379
LID - 10.5578/tt.20219709 [doi]
AB  - The effective treatment of asthma is important in terms of improving the quality 
      of life and decreasing the number of hospital admissions due to acute 
      exacerbations. Parasymphatic activity is increased in patients with asthma. This 
      is one of most important part of airway obstruction which has a great potential 
      for reversibility. The evidence about the synergic interaction between inhaled 
      corticosteroids (ICS), long acting beta-2 agonists (LABA), and long acting 
      muscarinic antagonists (LAMA) encourages the use of LAMA in asthma. Tiotropium 
      treatment was found to be successful in patients with recurrent exacerbations in 
      whom asthma was uncontrolled despite treatment with other add on treatments that 
      were recommended at GINA step 4. These findings triggered several clinical 
      studies on fixed dose ICS/LABA/LAMA for asthma treatment. Three studies that have 
      been published recently showed that fixed dose ICS/LABA/LAMA improved the lung 
      functions and decreased the exacerbation rate without increasing the dose of ICS 
      or LABA in asthma. In this review, the mechanisms of action of LAMA in asthma 
      were summarized and possible role of fixed dose ICS/LABA/ LAMA in asthma 
      treatment was discussed under the light of current literature.
FAU - Unsay Metan, Esra
AU  - Unsay Metan E
AD  - Division of Allergy and Clinical Immunology, Department of Chest Diseases, Ankara 
      University Faculty of Medicine, Ankara, Turkey.
FAU - Bavbek, Sevim
AU  - Bavbek S
AD  - Division of Allergy and Clinical Immunology, Department of Chest Diseases, Ankara 
      University Faculty of Medicine, Ankara, Turkey.
LA  - tur
PT  - Journal Article
PT  - Review
TT  - Sabit doz inhale kortikosteroid, uzun etkili beta-2 agonist ve uzun etkili 
      muskarinik reseptor antagonisti (IKS/LABA/LAMA) kombinasyonunun astim 
      tedavisindeki yer.
PL  - Turkey
TA  - Tuberk Toraks
JT  - Tuberkuloz ve toraks
JID - 0417364
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Muscarinic Antagonists)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adrenergic beta-2 Receptor Agonists/therapeutic use
MH  - *Asthma/drug therapy
MH  - Humans
MH  - *Muscarinic Antagonists/therapeutic use
MH  - Quality of Life
EDAT- 2021/09/29 06:00
MHDA- 2021/09/30 06:00
CRDT- 2021/09/28 07:14
PHST- 2021/09/28 07:14 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - 10.5578/tt.20219709 [doi]
PST - ppublish
SO  - Tuberk Toraks. 2021 Sep;69(3):369-379. doi: 10.5578/tt.20219709.